BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

HTG-Ventrex, Signalife, Inc.'s Contract Manufacturer, Acquired by Parker Hannifin Corporation (PH)


4/28/2008 8:30:16 AM

GREENVILLE, S.C., April 28 /PRNewswire-FirstCall/ -- Signalife, Inc. announced today that its contract manufacturer, Ventrex Inc., Ventura, CA, acquired by the Hi-Tech Group in September 2007, has been acquired by Parker Hannifin Corporation , Cleveland, OH as part of the Parker Hannifin strategic entry into the medical device manufacturing industry. The Hi-Tech Group, a 2007 Medical Design Excellence Award winner, combines the strength of Ventrex with other engineering, molding, assembly and plastics companies expanding its technical service offering to Signalife and the medical device industry. Signalife is pleased to have chosen Ventrex, Inc., a highly responsive and capable full service medical device contract manufacturer with ISO 13485 certification and FDA registration, as its contract manufacturer. With a broad array of process capabilities, foremost attention to quality, total responsiveness, and highly efficient operation, Ventrex offers superior value in medical device contract manufacturing services.

Dr. Budimir S. Drakulic, Signalife's Chief Technology Officer commented: "This acquisition is very important for Signalife's manufacturing capabilities. We have a great business relationship with HTG-Ventrex and are glad that they are now part of Medical Systems Division of Parker's Seal Group. Ventrex, Hi-Tech, and now Parker Hannifin remain totally committed to Signalife and its product's success."

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at www.signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state or governmental or international regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain import and export capabilities in the various countries containing buyers and resellers and hospitals and clinics and doctors for the Signalife devices, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.

CONTACT: Dr. Budimir Drakulic CTO of Signalife, +1-864-233-2300

Web site: http://www.signalife.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES